Search
BW-A 58C
go.drugbank.com/drugs/DB06740Experimentalmetabolite in man in vivo and also in human liver microsomes, where this is catalysed primarily by a 54 kDa CYP2C9 form of cytochrome P450, P450hB20-27. … BW-A 58C, also known as 2-(4-tert-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone, is an experimental naphthoquinone antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy
Synonyms: 2-(4'-t-Butylcyclohexyl)-3-hydroxy-1,4-naphthoquinoneTalbutal
go.drugbank.com/drugs/DB00306ApprovedIllicitTalbutal, also called 5-allyl-5-sec-butylbarbituric acid, is a barbiturate with a short to intermediate duration of action. Talbutal is a schedule III drug in the U.S.
Luteinizing hormone
go.drugbank.com/drugs/DB14741ApprovedInvestigationalMixtures: MENOGON 75 IU LIYOFILIZE TOZ ICEREN AMPUL,5 ADET, MENOPUR 150 IU IM VE SC ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 5 ADETPhellodendron amurense bark
go.drugbank.com/drugs/DB14370InvestigationalPhellodendron amurense bark is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Mixtures: Tag Wart RemoverPiperaquine
go.drugbank.com/drugs/DB13941ApprovedInvestigationalEurartesim was first authorized for market by the European Medicines Agency in October 2011.
NP-G2-044
go.drugbank.com/drugs/DB14995InvestigationalNP-G2-044 is under investigation in clinical trial NCT03199586 (Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)).
Albinterferon Alfa-2B
go.drugbank.com/drugs/DB05396InvestigationalHuman Genome Sciences modified interferon alpha to improve its pharmacological properties by using the company's proprietary albumin fusion technology. … Albumin-interferon alpha (Albuferon) is a novel, long-acting form of interferon alpha.
Rexin G
go.drugbank.com/drugs/DB16450InvestigationalRexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene. … It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. It is also being investigated for preventing SARSCOV-2 viral entry.
Muraglitazar
go.drugbank.com/drugs/DB06510InvestigationalIt belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha and gamma subtypes. … In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment is associated with a substantial reduction in triglycerides (TGs), an increase in HDL-C, and a modest decrease